Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Rhea-AI Summary
Elutia (Nasdaq: ELUT) announced it will release third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company said management will host a conference call and webcast the same day starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. Participants must register to receive a dial-in number and personalized PIN; registrants can also opt for a dial-out when the call begins.
A live and archived webcast will be available in the company’s Investors section at http://investors.elutia.com/. Attendees are asked to log in about 10 minutes before the scheduled start time.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ELUT declined 0.66%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
Dial-In: Click here
To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
This press release was published by a CLEAR® Verified individual.